XML 13 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2017
Sep. 30, 2016
CURRENT ASSETS    
Cash and cash equivalents $ 38,383,135 $ 85,366,448
Accounts receivable 937,313 75,000
Prepaid expenses 931,042 1,289,923
Other current assets 896,150 3,771,172
Short term investments 36,754,754  
TOTAL CURRENT ASSETS 77,902,394 90,502,543
Property and equipment, net 16,134,991 15,386,761
Intangible assets, net 20,889,546 22,164,868
Other assets 154,618 122,333
TOTAL ASSETS 115,081,549 128,176,505
CURRENT LIABILITIES    
Accounts payable 3,233,421 12,232,906
Accrued expenses 1,993,674 4,587,467
Accrued payroll and benefits 1,034,569 3,969,706
Deferred rent 440,580 440,580
Deferred revenue 13,283,006 2,569,792
Derivative liabilities 83,113 1,602,626
Note Payable 204,844 194,310
Other current liabilities 46,407 46,407
TOTAL CURRENT LIABILITIES 20,319,614 25,643,794
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 2,016,113 2,274,997
Deferred revenue, net of current portion 625,000 2,500,000
Note Payable, net of current portion 2,378,538 2,533,455
Other non-current liabilities 200,000 200,000
TOTAL LONG-TERM LIABILITIES 5,219,651 7,508,452
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 15,652 shares issued and outstanding as of June 30, 2017 and September 30, 2016   16
Common stock, $0.001 par value; 145,000,000 shares authorized; 74,772,103 and 69,746,685 shares issued and outstanding as of June 30, 2017 and September 30, 2016, respectively 167,142 162,116
Additional paid-in capital 512,032,168 493,844,909
Accumulated other comprehensive income (loss) (18,386) 7,449
Accumulated deficit (422,083,452) (398,435,043)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 90,097,472 95,579,447
Noncontrolling interest (555,188) (555,188)
TOTAL STOCKHOLDERS’ EQUITY 89,542,284 95,024,259
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 115,081,549 $ 128,176,505